CROWN BIOSCIENCE

Omni**Screen**™

Large-scale cancer cell line screening

Advance your lead compound to validated candidate through large-scale cancer cell line screening. Omni**Screen** provides key tumor killing activity data early in the drug development process to progress your anticancer agents with confidence.

- Time saving thanks to a rapidly scalable cell line bank, allowing you to make informed decisions early in your drug discovery process

- Clean results with high quality cell lines, fully verified by STR analysis and mycoplasma contamination free

- Consistent study design with well-established and controlled 96 or 384-well assay formats, amenable to assessing a range of agents including kinase inhibitors, epigenetic modulators, small and large molecules

- Flexibility in model choice of 50 or more cancer cell lines from an extensive collection of over 500 models

- Simplified target-driven model selection with Xeno**Base**, our online database collating genomic, transcriptomic, and pharmacological response data

- Reliable results with comparison treatment data available for quality control

- Extensive experience in combination assays and screens, including proprietary **CrownSyn™** drug combination analysis service

- Additional support from our experienced bioinformatics team to assist you with novel target and biomarker of response identification

- Seamless transition from *in vitro* to *in vivo* studies with matched cell line-derived xenograft models

Choose from four unique subpanels of cell lines:

- Omni**Panel**: a growing collection of more than 450 cancer cell lines

- Xeno**Select**: over 170 cancer cell lines with corresponding xenograft models to rapidly move to *in vivo* studies

- RNAseq**Panel**: over 190 cell lines with in-house RNAseq data for target identification

- Prime**Panel**: a growing collection of over 30 primary cancer cells derived from PDX models for improved clinical relevance

Cell-Based Compound Screening

Discovery Panel of Annotated Cancer Cell Lines

+ Drug

Responders

Non-Responders

Bioinformatics Analysis

Novel Target & Hypothesis

Biomarkers of Response

In Vitro Validation Panel

In Vivo Validation

Get in touch

Sales
US: +1 858 622 2900   busdev@Crownbio.com
UK: +44 870 166 6234   www.crownbio.com

Science
consultation@crownbio.com